Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/12374| Title: | The cost of new drugs in the treatment of hypertension--the Australian experience. | Austin Authors: | Louis, William J | Affiliation: | Austin Hospital, Heidelberg, Victoria, Australia | Issue Date: | 1-Dec-1989 | Publication information: | Cardiovascular Drugs and Therapy / Sponsored By the International Society of Cardiovascular Pharmacotherapy; 3(6): 825-7 | Abstract: | The treatment of hypertension by costly new drugs such as the angiotensin converting enzyme inhibitors, means that careful monitoring of health care expenditure is essential. If drugs like simvastatin come to be widely used, costs will mount even more. New drugs cannot be used indiscriminately. | Gov't Doc #: | 2518653 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/12374 | Journal: | Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy | URL: | https://pubmed.ncbi.nlm.nih.gov/2518653 | Type: | Journal Article | Subjects: | Angiotensin-Converting Enzyme Inhibitors.therapeutic use Anticholesteremic Agents.therapeutic use Antihypertensive Agents.therapeutic use Australia Cost-Benefit Analysis Humans Lovastatin.analogs & derivatives.therapeutic use Simvastatin |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.